Last week saw the newest third-quarter earnings release from Neuronetics, Inc. (NASDAQ:STIM), an important milestone in the company's journey to build a stronger business. Neuronetics reported ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Neuronetics is back on ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today ...

"Guidance... remains unchanged" with "total revenue between $160 million and $166 million," "gross margins... between 47% and 49%," "operating expenses in the range ...

PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Neuronetics, Inc., a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric ...

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth ...

Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basis Full year 2025 revenue of $149 ...

Neuronetics’ recent earnings call painted a picture of mixed sentiments, with notable achievements in revenue growth and cash flow management overshadowed by challenges such as declining NeuroStar ...